Larimar Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Larimar Therapeutics

10/11/2022 14:40

* Larimar Therapeutics Inc  LRMR.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 42 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Larimar Therapeutics Inc's reported EPS for the quarter
was a
loss of 37 cents​.
    * The mean earnings estimate of analysts had risen by
about 25% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Larimar Therapeutics Inc shares had fallen by 7.5% this
quarter and lost 72.6% so far this year.
    * The company reported a quarterly loss of $8.32 million.
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 02:40 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.42          -0.37          Beat
 Jun. 30 2022      -0.57          -0.47          Beat
 Mar. 31 2022      -0.51          -0.49          Beat
 Dec. 31 2021      -0.72          -0.50          Beat